No / Group IV metal complexes have previously shown promise as
novel anticancer agents. Here, we discuss the mechanistic and
cytotoxic nature of a series of group IV b-diketonate coordination
complexes. Clear evidence that the ligands are exchangeable
on the metal centre and that the b-diketonate ligands can
act as potential drug delivery vehicles of the group IV metal
ions was obtained. When evaluated for the cytotoxicity against
human colon adenocarcinoma (HT-29) and human breast adenocarcinoma
(MCF-7) cell lines, a general trend of decreasing
potency down the group IV metals was observed. The most
promising results obtained were for the hafnium complexes,
with the tris diphenyl b-diketonate hafnium complex exhibiting
IC50 values of 4.9 0.9 mm and 3.2 0.3 mm against HT-29
and MCF-7, respectively, which are comparable with the activity
of cisplatin against the same cell lines. This tri b-diketonate
hafnium complex is the first to show potent in vitro cytotoxic
activity. The results reported show that ligand design has a significant
effect on the cytotoxic potential of the complexes, and
that these group IV complexes warrant further evaluation as
novel metal-containing anticancer agents.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/9495 |
| Date | 06 1900 |
| Creators | Lord, Rianne M., Mannion, J.J., Hebden, A.J., Nako, A.E., Crossley, B.D., McMullon, M.W., Janeway, F.D., Phillips, Roger M., McGowan, P.C. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, No full-text in the repository |
Page generated in 0.0022 seconds